MALDI TOF Mass Spectrometry Imaging of Blood Smear: Method Development and Evaluation

Željko Debeljak 1,2, Ann-Christin Niehoff 3, Ana Bandjak 1, Dario Mandić 1,4, Milorad Zjalić 1,4, Marija Heffer 7, Stefan Mrđenović 8,9, Ivana Marković 1,4,*, Vatroslav Šerić 1,4

1 Clinical Institute of Laboratory Diagnostics, Osijek University Hospital, J. Huttlera 4, 31 000 Osijek, Croatia; zeljko.debeljak@gmail.com (Z.D.); ana.bandjak@gmail.com (A.B.); dario.mandic@gmail.com (D.M.);
2 Department of Internal Medicine, Family Medicine and History of Medicine, Faculty of Medicine Osijek, J. Huttlera 4, 31 000 Osijek, Croatia
3 European Innovation Center, Shimadzu Europa GmbH, Albert-Hahn-Straße 6-10, 47269 Duisburg, Germany; acn@shimadzu.eu
4 Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine, JJ Strossmayer University of Osijek, J. Huttlera 4, 31 000 Osijek, Croatia
5 Clinical Institute of Transfusion Medicine, Osijek University Hospital, J. Huttlera 4, 31 000 Osijek, Croatia; bosnjak.bojana@kbo.hr
6 Department of Microbiology, Parasitology and Clinical Laboratory Diagnostics, Faculty of Medicine, JJ Strossmayer University of Osijek, J. Huttlera 4, 31 000 Osijek, Croatia
7 Department of Medical Biology and Genetics, Faculty of Medicine, JJ Strossmayer University of Osijek, J. Huttlera 4, 31 000 Osijek, Croatia; mheffer@mefos.hr (M.H.); mzjalic@mefos.hr (M.Z.)
8 Department of Hematology, Internal Medicine Clinic, Osijek University Hospital, J. Huttlera 4, 31 000 Osijek, Croatia; stefan.mrdjenovic@kbo.hr
9 Department of Internal Medicine, Family Medicine and History of Medicine, Faculty of Medicine Osijek, JJ Strossmayer University of Osijek, J. Huttlera 4, 31 000 Osijek, Croatia
*
Correspondence: i.markov00@gmail.com; Tel.: +385-(031)-511-641

Abstract: The aim of this study was to develop and evaluate matrix assisted LASER desorption ionization (MALDI) time-of-flight (TOF) mass spectrometry imaging (MSI) of blood smear. Integrated light microscope and MALDI IT-TOF mass spectrometer, together with a matrix sublimation device, were used for analysis of blood smears coming from healthy male donors. Different blood plasma removal, matrix deposition, and instrumental settings were evaluated using the negative and positive ionization modes while agreement between the light microscopy images and the lateral distributions of cellular marker compounds served as the MSI quality indicator. Red and white blood cells chemical composition was analyzed using the differential m/z expression. Five seconds of exposure to ethanol followed by the 5 min of 9-aminoacridine or α-cyano-4-hydroxycinnamic acid deposition, together with two sets of instrumental settings, were selected for the MALDI TOF MSI experiments. Application of the thin and transparent matrix layers assured good correspondence between the LASER footprints and the preselected regions of interest. Cellular marker m/z signals coincided well with the appropriate cells. A metabolite databases search using the differentially expressed m/z produced hits which were consistent with the respective cell types. This study sets the foundations for application of blood smear MALDI TOF MSI in clinical diagnostics and research.

Keywords: MALDI TOF; mass spectrometry imaging; blood smear; method development

1. Introduction

Red blood cells (RBC) circulate for approximately 4 months through the human vascular system [1]. In this way, cells come in contact with each organ and tissue, which affects RBC appearance and leaves a unique signature. Different mechanical obstacles that may exist in circulation cause visible deformation of the blood cells. Even blood plasma
chemistry changes, caused by some liver or kidney diseases, lead to specific RBC membrane chemical changes that manifest themselves as deformations detectable by light microscopy [2]. Unfortunately, the light microscopy of native or even stained blood smears cannot detect chemical signatures carried by blood cells which are caused by other organ pathologies. Flow cytometry and immunohistochemical techniques may partially overcome this shortage, but these techniques are not suitable for simultaneous assessment of numerous metabolites and other small molecules [1]. On the other end of the analytical spectrum lies liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS), which enables quantification of different endo- and xenobiotics in blood cell homogenates but cannot assign contents of different small molecules to individual cells [3,4]. Also, many sample-preparation steps needed for separation of blood cell fractions, cellular homogenization, and homogenate prefractionation may compromise the LC-MS/MS-based approach to average RBC or white blood cell (WBC) chemical content determination and make this approach unsuitable for routine diagnostics.

Light microscopy-based morphology analysis and blood cell differentiation using blood smear is the least invasive yet informative procedure that is widely used in different medical fields like hematology, immunology, infectology, oncology, blood transfusion, organ transplantation, etc. [1]. Adding information about the chemical composition of individual cells to the already available count and morphology of blood cells is expected to bring significant advancements to the respective medical fields [5,6]. Blood cells that were in contact with tissues affected by emerging pathological process are expected to be tagged by a chemical imprint of the process. For timely diagnosis, a fraction of the blood cells that are chemically tagged should be detected. Mass spectrometry imaging (MSI) combines the advantages of light microscopy and MS, making it suitable for assessment of the chemical composition of individual blood cells present in blood smear. Different MSI techniques may provide information about the chemical composition of tissues and organs [7,8]. However, a blood cell diameter of 5–25 \( \mu m \) represents an important constraint for the application of most available MSI technologies. Of the commercially available techniques that can be applied in routine diagnostic settings, only the secondary ion mass spectrometry (SIMS) and some matrix-assisted LASER desorption/ionization (MALDI) time-of-flight (TOF) MS instruments provide a lateral resolution of 10 \( \mu m \) or better, which is required for reliable MSI of such small objects [9–13]. When it comes to blood smear that contains dozens of different blood cells per 400× magnification field, besides the need for high lateral resolution, application of the integrated mass and light microscopy instruments seems mandatory: shifts of even 5 \( \mu m \) may lead to miss-assignment of a recorded mass spectrum to cells that surround the cell that have been shot by a LASER beam.

Thanks to plasma, blood cells are easily attached to different surfaces including indium tin oxide (ITO) slides. However, plasma that covers all cells contains many different small molecules such as lipids, which should be removed if the cellular content is to be analyzed [14]. The least sample-integrity-compromising way to remove the plasma components is to immerse the ITO slide covered by the blood smear in a polar solvent such as ethanol (EtOH), keeping in mind the possibility of unwanted cell lysis and lateral diffusion. Besides the removal of interfering plasma components, ion suppression is also reduced this way [15]. To achieve the highest possible signal intensities coming from the small objects using MALDI TOF MSI, the prepared blood-smeared ITO slide should be covered by the appropriate matrix. The matrix crystals should be as small as possible to match the cells’ diameter: this can be achieved by sublimation [16]. To eliminate the possibility of ITO slide shifts, light microscopy images of blood smear should be recorded after the matrix has been applied: this way, MSI and light microscopy images are recorded without the need for any ITO slide movements. For that purpose, the matrix layer should be thin and transparent, which also makes the matrix deposition by sublimation a method of choice. The blood cell size also dictates the LASER setting selection. Obtaining a small LASER footprint while keeping a reasonable \( m/z \) signal intensity might be challenging [17,18]. To meet the requirements for a small LASER spot footprint, low LASER energies and a low...
number of shots per pixel should be used. This way, the mixing of spectra coming from neighboring cells is minimized.

The aim of this study was to develop and evaluate the MALDI TOF MSI of blood smear. To the best of our knowledge, this is the first attempt to achieve this goal. The approach described in the preceding text was applied, and correspondences between the cellular distribution obtained using light microscopy; the recorded lateral distribution of cellular markers such as heme, adenosine triphosphate (ATP), and inosine monophosphate (IMP); and the corresponding m/z signal intensities were used as the MALDI TOF MSI quality indicators. Differentially expressed m/z signals coming from RBC and WBC recorded using optimal sample preparation and instrumental conditions were analyzed.

2. Results
2.1. Method Development

A macroscopic image of a holder containing an ITO slide covered by 2 blood smears is given in Figure 1. Due to optimal cell dispersion, a 2-µL blood drop volume was chosen.

![Figure 1. Two-microliter blood drops smeared on two ends of the same indium tin oxide (ITO) slide, with the arrows pointing to optimal cell dispersion zones: cells lying close to each other disable unequivocal mass spectrometry imaging (MSI) analysis, while too much dispersion of cells yields too few cells.](image)

Removal of the blood plasma that covers cells of interest was performed using polar solvents. This procedure causes, among other things, WBC destruction, leaving cell remnants called smudge cells, the count of which served as the sample integrity quality indicator (Figure 2). As a compromise between the cell destruction and removal of interfering plasma components, 5 s of exposure to 96% EtOH was selected for the following MSI experiments.

The selection of 9-aminoacridine (9AA) and α-cyano-4-hydroxycinnamic acid (CHCA) deposition conditions, LASER intensities, and pitch sizes for D0 and D1 instrumental settings was performed using heme, ATP, and IMP signal intensities as quality indicators: the results are given in the Supplementary Materials (Figures S1–S5). Five-minute sublimation of 9AA or CHCA followed by 105 s of recrystallization was selected for the following experiments. The method development produced the following instrumental settings:

1. D0: 80 nJ LASER energy (LASER intensity of 12% and 100 Hz frequency), x and y pitch sizes of 8 and 7 µm, and 50 LASER shots per pixel were predefined;
2. D1: 95 nJ LASER energy (LASER intensity of 14% and 40 Hz frequency), x and y pitch sizes of 8 and 6 µm, and 30 LASER shots per pixel were predefined.

During method development, the focus was on the m/z signal intensities of cellular markers. Complete total ion count (TIC)-normalized spectra recorded using the selected instrumental conditions are given in Figure 3.
Figure 2. White blood cell (WBC) destruction due to exposure to solvents producing so-called “smudge cells”.

Figure 3. Comparison of total ion count (TIC) normalized spectra (upper: m/z 200–600 and lower: 600–900 Da) averaged over all pixels recorded using the selected D0 and D1 instrumental settings: (a) D0 settings and 9-aminoacridine (9AA) matrix/negative ionization, (b) D1 settings and 9AA matrix/negative ionization, (c) D0 settings and α-cyano-4-hydroxycinnamic acid (CHCA) matrix/positive ionization, and (d) D1 settings and CHCA matrix/positive ionization.
LASER shot diameter and accuracy are of critical importance for the reliable generation of MSI and individual cell chemical composition assessment. Figure 4 shows regions of interest (ROI) designated by yellow squares before and after the MSI was performed using the selected D0 and D1 settings.

Cells surrounding the yellow square in Figure 4a show that the same square was shot by LASER in Figure 4b. For example, it can be noticed that the RBC, which lies in the upper left corner of the square in Figure 4a, has been shot by the LASER and that the corresponding LASER footprint covers the same cell in Figure 4b. The LASER footprint visible in Figure 4b corresponds to the LASER-caused matrix changes not cellular changes.

2.2. Evaluation of the Blood Smear MSI

Quality of MSI represents the ultimate goal of the method development: examples of images recorded using selected sample preparation and instrumental settings are given in Figure 5.

Figure 5. Lateral distribution of cellular markers overlaid on light microscopy images: ATP (a,e), heme (b,d,f,h), and inosine monophosphate (IMP) (c,g). MSI (a–d) was recorded using the selected D0, while images (e–h) were recorded using selected D1 settings. The 9AA matrix and negative ionization were used for recording images (a,b,e,f). The CHCA matrix and positive ionization were used for recording images (c,d,g,h). Scale bar corresponds to 5 μm.
Differential \( m/z \) signal expression analysis relied on a comparison of the RBC and WBC signals with signals coming from the plasma remnants: the statistically significant results of the two sample \( t \)-test using samples coming from 6 different blood donors are given in Tables 1 and 2. Table 1 contains counts of the differentially expressed \( m/z \) signals that were recorded using different instrumental settings and different matrices (Figure 3a–d). Table 2 contains metabolites identified in the Human Metabolome Database (HMDB): only the single database hits having a Kyoto Encyclopedia of Genes and Genomes (KEGG) identifier which belongs to the group of endogenous or exogenous but essential compounds are presented, i.e., multiple database search hits, including isobaric ions, were excluded from the following analysis. The results given in Table 2 were integrated over all MSI settings tested.

**Table 1. Differentially expressed \( m/z \) signal counts.**

| Instrumental Settings | \( m/z \) | D0  | 9AA | CHCA | D1  | 9AA | CHCA |
|-----------------------|----------|-----|-----|------|-----|-----|------|
| Cell Type             |          |     |     |      |     |     |      |
| RBC                   | 200–900  | 60  | 100 | 29   | 82  | 60  | 100  |
| WBC                   | 200–900  | 68  | 145 | 80   | 100 | 80  | 100  |

\( ^a \) Results coming from two consecutive \( m/z \) ranges were combined.
Table 2. Metabolites differentially expressed in RBC and WBC relative to plasma: metabolites were assigned to appropriate \( m/z \) signals by Human Metabolome Database (HMDB) and Kyoto Encyclopedia of Genes and Genomes (KEGG) database searches using ±0.025 Da tolerance. Multiple database search hits like isobars were excluded: only the single hits that belong to endogenous or exogenous but essential compounds are given.

| \( m/z \)     | Adduct | KEGG ID | Metabolite                                      | Cell/Plasma | Instrumental Settings | Cell Type |
|--------------|--------|---------|-------------------------------------------------|-------------|-----------------------|-----------|
| 367.99194    | M-H2O-H | C00705  | 2'-Deoxycytidine diphosphate (dCDP)             | 0.8         | D0−                   | RBC       |
| 423.02167    | M-H    | C0068   | Thiamin diphosphate                             | >0.1        |                       |           |
| 607.17777    | 2M-H   | C12270  | \( N \)-Acetylaspargylglutamic acid            | 0.3         |                       |           |
| 743.53308    | 2M-H   | C13828  | Cervonoyl ethanolamide                          | 6.5         |                       |           |
| 755.09679    | M-H    | C06197  | Diadenosine triphosphate                        | >0.1        |                       |           |
| 821.05335    | 2M-H   | C00206  | 2'-Deoxyadenosine 5'-diphosphate                | >0.1        |                       |           |
| 221.97144    | M+K    | C16511  | l-Homocysteic acid                              | 1.6         |                       |           |
| 265.96063    | M+K    | C03287  | l-GLUTAMIC acid 5-phosphate                     | 1.2         |                       |           |
| 326.77131    | 2M+H   | C06232  | Molybdate                                       | 2.0         |                       |           |
| 415.84174    | M+H-H2O| C01060  | 3,5-Diiodo-l-tyrosine                           | 0.8         |                       |           |
| 456.0047     | M+H-2H4O| C00131  | 2'-Deoxyadenosine 5'-triphosphate (dATP)        | 1.4         |                       |           |
| 500.04952    | M+Na   | C00513  | CDP-glycerol                                    | 2.8         |                       |           |
| 514.96755    | M+Na   | C01345  | 2'-Deoxyinosine triphosphate                    | 0.5         |                       |           |
| 694.83621    | 2M+Na  | C05704  | Selenocystine                                   | 0.7         |                       |           |
| 790.43199    | M+K    | C06125  | 3-O-Sulfogalactosylceramide (d18:1/14:0)        | 0.7         |                       |           |
| 418.04554    | M+K    | C03451  | \( S \)-Lactoylglutathione                      | 0.6         |                       |           |
| 498.14504    | M+K    | C00440  | 5-Methyltetrahydrofoleric acid                  | 1.2         |                       |           |
| 616.17073    | M+H    | C00302  | Heme                                            | 1.6         |                       |           |
| 652.04788    | M+H-2H2O| C04426  | Uridine diphosphate acetylgalactosamine 4-sulfate| 0.7         |                       |           |
| 774.11178    | M+H-2H2O| C0024   | Acetyl-CoA                                      | 0.6         |                       |           |
| 796.1011     | M+H    | C00798  | Formyl-CoA                                      | 0.9         |                       |           |
| 338.96305    | 2M-H   | C11499  | (S)-3-Sulfonatolactate                          | 0.5         |                       |           |
| 367.99194    | M-H2O-H| C00705  | dCDP                                           | 0.6         |                       |           |
| 409.06403    | 2M-H   | C02470  | Xanthurenic acid                                | 1.7         |                       |           |
| 601.60302    | 2M-H   | C00836  | Sphinganine                                     | 0.6         |                       |           |
| 409.00689    | M-H2O-H| C00104  | Inosine 5'-diphosphate (IDP)                    | 0.8         |                       |           |
| 426.95079    | 2M-H   | C0054   | 2-Oxo-3-hydroxy-4-phosphobutanoic acid          | 17.8        |                       |           |
| 488.97877    | M-H2O-H| C0081   | Inosine triphosphate (ITP)                      | 3.2         |                       |           |
| 506.11841    | M+Cl   | C03204  | 10-Formylidihydrofolate                         | 9.2         |                       |           |
| 506.99341    | M-H    | C00081  | ITP                                             | 1.9         |                       |           |
| 724.08168    | M-H2O-H| C00006  | NADP                                           | >0.1        |                       |           |
| m/z     | Adduct   | KEGG ID | Metabolite                                      | Cell/Plasma | Instrumental Settings | Cell Type |
|---------|----------|---------|------------------------------------------------|-------------|-----------------------|-----------|
| 743.53308 | 2M-H     | C13828  | Cervonoyl ethanolamide                          | 0.3         |                       |           |
| 753.97899 | M+Cl     | C02739  | Phosphoribosyl-ATP                              | >0.1        |                       |           |
| 806.70364 | M-H2O-H  | C01190  | GlcCer(d18:1/25:0)                              | >0.1        |                       |           |
| 701.98895 | M+H-H2O  | C01060  | 3,5-Diiodo-L-tyrosine                           | 0.7         |                       |           |
| 709.0265  | 2M+K     | C05925  | Dihydroneopterin phosphate                      | 1.7         |                       |           |
| 762.92406 | 2M+H-H2O | C00119  | Phosphoribosyl pyrophosphate                    | 0.6         |                       |           |

Table 2. Cont.

| m/z     | Adduct   | KEGG ID | Metabolite                                      | Cell/Plasma | Instrumental Settings | Cell Type |
|---------|----------|---------|------------------------------------------------|-------------|-----------------------|-----------|
| 706.13261 | M+Na     | C04856  | (6R)-5,10-methenyltetrahydrofolate              | 0.7         |                       |           |
| 728.10302 | M+H-H2O  | C19851  | ADP-ribose 1”-2” cyclic phosphate               | 0.4         |                       |           |
| 779.09063 | M+Na     | C06197  | Diadenosine triphosphate                        | 1.0         |                       |           |
| 865.13597 | 2M+H     | C05692  | Se-Adenosyl-L-selenohomocysteine                | 0.5         |                       |           |
3. Discussion

3.1. Sample Preparation and Instrumental Settings

Blood smeared over the ITO slide forms a single cell layer that is firmly attached to the surface even without a fixation agent (Figures 4–6). Zones of different cell dispersions/densities are clearly visible (Figure 6). Among those, the zone containing the lowest surface density of blood cells that had not been clumped together was chosen for MSI. The 9AA and CHCA matrices deposited by sublimation lasting 5 min formed transparent layers over the smear (Figures 4 and 5), but at least in the D0 case, $m/z$ signals recorded using a negative ionization were relatively weak, which may be attributed to the low LASER energies and thin matrix layer (Figure 3). The noisy appearance of spectra recorded using negative ionization/9AA matrix (Figure 3a,b) may be associated with easily ionized free fatty acids (FFA) and phospholipids: both blood plasma and different blood cells contain significant quantities of these compounds [4,14,19]. Even in the best-case scenarios provided by short exposure to EtOH and MeOH, there was a significant trade-off between the sample integrity and plasma removal (Figure 1): careful visual inspection of Figure 4 confirms the existence of plasma remnants in regions surrounding blood cells. All blood cells, while circulating in vascular system, are immersed in the plasma: plasma removal using more effective agents not only could cause profuse cell destruction but also could compromise the assessment of blood cell chemical composition. However, stronger heme and ATP $m/z$ signals recorded in negative ionization/9AA mode using selected D1 in comparison to D0 settings suggest that oversampling may explain the noisy appearance of the spectra: smaller LASER spot sizes may leave blood cells intact, leading to domination of easily ionized plasma lipids covering the cell surfaces (Figure 3a vs. Figures 3b and 5a,b vs. Figure 5e,f, Supplementary Figures S3–S5) [18]. The mass spectra given in Figure 3a were recorded using the same slide as in Figure 3b. A lower LASER energy in the D0 case is the most probable cause of different appearances in these figures. A D0 vs. D1 comparison using positive ionization/CHCA matrix, heme and IMP as cellular markers shows the same trend: weak intracellular marker signals are associated with nonoverlapping low energy LASER spots, i.e., D0 settings, while application of oversampling, i.e., D1 settings, produces stronger $m/z$ signals probably due to the increased cell wall permeability and/or more desorbed material (Figure 3c vs. Figures 3d and 5c,d vs. Figure 5g,h, Supplementary Figures S2, S4, and S5).

Evaluation of the correspondence between the light microscopy image and LASER footprint preceded the MSI experiments. As shown in Figure 4, total LASER footprints recorded using the selected D0 or D1 settings correspond well with the preselected ROI. Graphical representation of the following MSI experiments is given in Figure 5. As expected, the strongest signal intensities coming from the cellular markers are located over or in close vicinity to the cells while the non-populated spaces correspond to the weaker signals. Lateral distribution of the cellular markers is consistent with the cell type specificity: while heme-associated $m/z$ signals cover primarily RBC, the ATP-associated $m/z$ signals are shared by WBC and RBC [1]. IMP signals are too weak to be analyzed in detail, but even these may be detected over some RBC, as expected [3]. Individual cells are not expected to have the same content of metabolites. Therefore, the different $m/z$ signal intensities associated with individual cells is an expected outcome. However, some signals are “smeared” over the spaces surrounding cells: in the D1 case, this can be attributed to LASER spot overlap and to the leakage of cellular components as a result of the EtOH treatment or cell death. LASER spot overlap raises the possibility of mixing the mass spectra coming from pixels of interest with the spectra of its surroundings (Figure 4). Besides, in some instances, the LASER spot center does not perfectly match the center of some particular cell. On the other hand, in the D1 case, most cells are covered by chosen $m/z$ signals, but in the D0 case, chosen $m/z$ signals cover a smaller fraction of existing cells (Figure 5). Partial coverage of blood cells with $m/z$ signals coming from the cellular markers in the D0 case probably does not provide the true cellular markers’ content: it is rather an artefact of weak desorption or ionization.
Author Contributions: Supplementary Materials:

Conceptualization, Ž.D. and A.-C.N.; methodology, A.B., D.M., M.H., and S.M.; All authors have read and agreed to the published version of the manuscript.

Application of the t-test to MSI sets produced differentially expressed m/z for each cell type, each matrix, and each instrumental setting evaluated (Table 1): RBC and D1 settings produced fewer differentially expressed m/z in comparison to WBC and D0 settings, respectively, while the CHCA matrix enabled detection of more differentially expressed m/z then the 9AA matrix. The first trend is supposed to be associated with the fact that RBCs have less complex metabolic networks and more resistant membranes. This result may also mean that RBCs show greater cell-to-cell variability: 5 RBCs vs. only 1 WBC per blood donor were included in differential m/z expression analysis. The second trend is supposed to be associated with mixing of the neighboring pixel’s spectra: in the case of D0 experiments, which did not cause LASER spot overlap, neighboring LASER spot spectra mixing is less probable (Figure 4). However, due to the stronger signals, only the application of D1 settings in positive ionization mode produced significant differences in the heme-associated m/z signal between the RBC and plasma. The third trend reflects the greater fraction of neutral and basic metabolites that are prone to positive ionization and the somewhat stronger signals coming from CHCA-treated samples.

3.2. Human Metabolome Database Search

Differential expression analysis of the m/z signals coming from the RBC, WBC, or blood plasma was performed using t-test. The cells were compared to plasma, and significantly different m/z signals entered the HMDB and KEGG search using ±0.025 Da tolerance. Single hits coming from this search that correspond to endogenous or essential compounds were integrated over all evaluated chemical and instrumental settings, while multiple search hits, including isobaric compounds, were eliminated. In comparison to the total count of differentially expressed m/z signals given in Table 1, the total count of differentially expressed metabolites given in Table 2 is substantially lower due to the excluded multiple database search hits and due to the m/z values that did not correspond to any of existing database entries.

Figure 6. Regions of interest (ROI) selection: red ellipses cover RBCs, light blue ellipse covers WBCs, and yellow ellipses cover plasma remnant regions. Light microscopy image: blood smear covered by a 9AA matrix.
The results presented in Table 2 corroborate the association of differentially expressed metabolites with appropriate blood cell types. Among the identified metabolites, the ones in which cellular content decreased in comparison to plasma predominated. RBC and WBC contents of lipids like acetyl-CoA are seemingly decreased, but this primarily reflects the fact that blood plasma represents the major medium for their transport. The same stands for some hormone metabolites like 3,5-diiodo-L-tyrosine and small peptides like N-acetylaspartylglutamic acid. The energetic demands of cells, especially WBC, are reflected in the decreased content of NADPH, NADHX, etc. The number of metabolites for which content is increased in cells in comparison to plasma is not too many, but these metabolites may provide more convincing evidence of blood smear MSI performance. Contents of dATP were increased in both cell types in comparison to plasma. In WBC, dATP is a substrate and inhibitor of DNA synthesis, and in RBC, it may serve as a secondary source of energy in case of ATP depletion [20]. This metabolite inhibits DNA synthesis in WBC by inhibition of ribonucleotide reductase, but it also inhibits S-adenosylhomocysteine (SAH) hydrolase in both cell types. This in turn leads to depletion of deoxynucleotides like dCDP in WBC and to accumulation of demethylated metabolites like L-homocysteic acid accompanied by depletion of methylated products like 5-methyltetrahydrofolate acid and (6R)-5,10-methylenetetrahydrofolate detected in RBC and WBC, respectively. Among the metabolites which content is increased in both cell types, L-glutamic acid 5-phosphate stands out: it is required for the removal of ammonia from the cells, and as a precursor for the glutathione synthesis, it is essential for the proper response to oxidative stress. Therefore, it is expected that L-glutamic acid 5-phosphate’s content is increased in both cell types in comparison to plasma. On the other hand, the accumulation of heme and thiamine diphosphate is specific to RBC: heme plays a crucial role in RBC-mediated oxygen transport, while thiamine pyrophosphate plays a crucial role in the RBC-specific pentose phosphate pathway. Dihydroneopterin phosphate accumulates in WBC as expected due to its role in WBC-mediated inflammatory response [21]. Selenoproteins and molybdate listed in Table 2 are endogenous compounds physiologically present in the blood cells, and their roll in cell metabolism is described in the literature [22–24]. The association of the rest of the metabolites (Table 2) with different cell types is omitted since they are either redundant or there is a lack of evidence of their cell-specific role and expression.

4. Materials and Methods

4.1. Human Subjects

This study was conducted at the Osijek University Hospital, Croatia from March to July 2020 in accordance with the Declaration of Helsinki. The study was approved by the hospital’s ethical committee. Fifty-eight subjects were enrolled in the study. All subjects were apparently healthy male blood donors aged 20–60 who provided written consent for participation in the study.

4.2. Sample Preparation

Approximately 3 mL of blood from the antecubital vein of each subject was collected in the sample tube containing EDTA anticoagulant (Becton Dickinson, Plymouth, UK). Sample suitability evaluation that involved RBC and WBC counts was performed using the XN-2000 hematology analyzer (Sysmex, Kobe, Japan): blood samples characterized by the WBC or RBC counts beyond the reference ranges were excluded from the study [1]. Unless stated otherwise, 2 µL of each blood sample was smeared over the unused ITO slide of 15–25 Ω/sq surface resistivity (Sigma Aldrich, St. Louis, MO, USA). The smeared blood was left to dry on the ITO slide for 5 min under room conditions. Two blood smears per each ITO slide were prepared and analyzed within the 24 h period after the venipuncture took place.

ITO slides with blood smears were immersed in methanol Ph. Eur. (MeOH; Merck, Darmstadt, Germany), chloroform p.a. (CHCl3; Kemika, Zagreb, Croatia), or 96% EtOH Ph. Eur. (Merck, Darmstadt, Germany) for 1, 2, 5, and 10 s. The percentage of disintegrated
WBC called “smudge cells” associated with exposure to the solvents was used only as the sample integrity indicator (these cells were not analyzed). Due to favorable sublimation properties and transparent appearance, 9AA (Sigma Aldrich, St. Louis, MO, USA) and CHCA (Sigma Aldrich, St. Louis, MO, USA) matrices were chosen for the study. Three-, five-, and eight-min lasting matrix sublimation procedures were evaluated using iMLayer (Shimadzu, Kyoto, Japan) in accordance with the manufacturer’s settings. Recrystallization was performed in a closed container heated to 37 °C for 300 s or 70 °C for 105 s using 5% v/v MeOH:H₂O solution: blood-smeared ITO slides covered with the matrix were placed above the solution. Indicators of the matrix deposition quality were the visibility of matrix-covered WBC and TIC-normalized signal intensities of cellular markers like heme, ATP, and IMP averaged over all pixels. The corresponding $m/z$ values are given in Table 3. A tolerance of ±0.025 Da was used for the detection of corresponding signals in the recorded mass spectra.

Table 3. Cellular marker compounds used as the MSI quality indicators.

| Ionization | Cellular Marker Compound | Adduct Ion          | Monoisotopic m/z (Da) |
|------------|--------------------------|---------------------|-----------------------|
| Negative   | ATP                      | [M − H]⁻             | 505.988               |
|            | Heme (Fe II)             | [M − H]⁻             | 615.170               |
| Positive   | IMP                      | [M + Na]⁺            | 371.037               |
|            | Heme (Fe III)            | [M]⁺                 | 616.177               |

4.3. Instrumental Settings

All MSI experiments were performed using iMScope Trio (Shimadzu, Kyoto, Japan). The instrument was equipped with a light microscope, Nd:YAG LASER (355 nm), containing an atmospheric pressure MALDI source and an ion trap (IT) TOF MS running in the reflectron mode. The light microscopy settings used throughout the study included non-stained samples, 400× magnification, and an incident or transmitted light source. The critical parameters for instrumental settings selection were LASER spot size and total LASER footprint, which should conform to the analysis of individual blood cells dispersed over the ITO surface. Different instrumental settings were examined (Supplementary Figures S2–S5), among which two experimental settings which produced the best results were selected for the following experiments: the first set was associated with the nominal LASER diameter (named D0) of 5 µm and the second one (named D1) was associated with the nominal LASER diameter of 10 µm. To accomplish better MS sensitivity while keeping the LASER spot small, narrow $m/z$ ranges were coupled to low LASER frequency and a low number of LASER shots per pixel. If not stated otherwise, each MSI experiment involved recording mass spectra across two neighboring $m/z$ ranges: 200–600 and 600–900 Da using negative and positive atmospheric MALDI ionization and maximum source voltage. Four MS images per MSI experiment using D0 settings were recorded, and they contained ca. 100 pixels. The same stands for the D1 settings. Some settings were fixed throughout the study: D0 settings always involved 50 spectra per pixel coupled with 100 Hz LASER frequency, while D1 settings always involved 30 spectra per pixel coupled with 40 Hz LASER frequency. On the other hand, different LASER energies and pitch sizes were tested during method development. LASER energies ranging from 69 to 130 nJ together with x and y pixel pitch sizes ranging from 6.0 and 5.0 to 8.0 and 7.0 µm were evaluated as a part of D0 setting selection, while energies ranging from 95 to 194 nJ together with x and y pixel pitch sizes ranging from 8.0 and 6.0 to 14.0 and 12.0 µm were evaluated as a part of D1 setting selection. $m/z$ signal intensities coming from the cellular markers were used as quality indicators. All MSI experiments involved two blood smears coming from two different donors. After the method development was finished, the selected MSI conditions were applied to the analysis of differentially expressed $m/z$. A new set of blood smears was used for that purpose.
4.4. Data Analysis

Imaging MS Solution 1.30.06 (Shimadzu, Kyoto, Japan) was used for the average mass spectrum visual inspection. All MSI were generated by IMAGEREVEAL 1.1 (Shimadzu, Kyoto, Japan). Lanczos interpolation, median smoothing, and ±0.025 Da tolerance were used for that purpose. Targeted analysis was followed by a differential analysis. Targeted analysis was performed using TIC-normalized centroid signals found in 0.020 Da m/z bins, for which the intensity was greater than 0.1% of the highest signal in the mass spectrum. Five RBCs, one WBC, and three plasma remnant ROIs per smear coming from six different individuals were selected for the collection of RBC-, WBC-, and plasma-specific mass spectra (Figure 6).

This procedure was applied on 8 different sets of MSI that were recorded using D0 or D1 LASER settings, two different m/z ranges, and positive or negative ionization. Recorded spectra were preprocessed as described earlier in the text, but only 500 most intense m/z per single MSI set were kept for the differential expression analysis. t-test and 0.05 significance limit were used for the comparison of the RBC spectra or WBC spectra with the spectra coming from the seemingly empty areas of each smear that actually contained some blood plasma remnants. The obtained differentially expressed m/z were used as inputs for the HMDB search using ±0.025 Da tolerance [25]: unique HMDB hits associated with the endogenous and exogenous essential compounds having KEGG ID were used for the differential analysis [26].

5. Conclusions

Sample preparation and instrumental settings suitable for the MALDI TOF MSI of blood smear were developed. The sample preparation consisted of transparent matrix deposition by sublimation onto ITO slides containing blood smears briefly treated with EtOH. Two sets of instrumental MALDI TOF MSI conditions were evaluated using cellular markers and differential expression analysis. MSI coincided well with the light microscopy images recorded using integrated light microscope and MALDI TOF MS. Lateral distributions of cellular markers were consistent with the respective cell type marker’s content. Differential analysis performed on RBC and WBC followed by the metabolite database search produced hits that were consistent with the respective cell types. In conclusion, this study sets the foundations for application of blood smear MSI in clinical diagnostics and research.

Supplementary Materials: Supplementary materials can be found at https://www.mdpi.com/1422-0067/22/2/585/s1.

Author Contributions: Conceptualization, Ž.D. and A.-C.N.; methodology, A.B., D.M., M.H., and M.Z.; resources, B.B. and VŠ.; writing—original draft preparation, Ž.D., I.M., M.H., and S.M.; All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the European Regional Fund and Croatian Ministry of Science, Infrastructural Project grant KK.01.1.1.02.0015. The APC was funded by Shimadzu d.o.o. Croatia.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of University Hospital Osijek, Croatia (Protocol code R2-5459/2020. Date of approval: 12 May 2020).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Data Availability Statement: The raw data is available on request that should be send to: zeljko.debeljak@gmail.com.

Acknowledgments: We would like to thank Andreas Schnapp, Shimadzu Europa for the technical support.

Conflicts of Interest: A.-C.N. is employee of Shimadzu Europa GmbH, Germany. Other authors have no potential conflict of interest to declare.
Abbreviations

9AA  9-aminoacridine  
ATP  Adenosine triphosphate  
CHCA  A-cyano-4-hydroxycinnamic acid  
EDTA  Ethylenediaminetetraacetic acid  
HMDB  Human metabolome database  
IMP  Inosine monophosphate  
IT  Ion trap  
ITO  Indium tin oxide  
KEGG  Kyoto Encyclopedia of Genes and Genomes  
MALDI  Matrix assisted LASER desorption ionization  
LC-MS/MS  Liquid chromatography coupled to tandem mass spectrometry  
MSI  Mass spectrometry imaging  
RBC  Red blood cells  
ROI  Region of interest  
SIMS  Secondary ion mass spectrometry  
TIC  Total ion count  
TOF  Time-of-flight  
WBC  White blood cells

References

1. McKenzie, S.B.; Williams, L. Clinical Laboratory Hematology, 3rd ed.; Pearson: Upper Saddle River, NJ, USA, 2015. Available online: https://www.pearson.com/us/higher-education/program/Mc-Kenzie-Clinical-Laboratory-Hematology-3rd-Edition/PGM229351.html (accessed on 29 July 2020).

2. Bonomini, M.; Pandolfi, A.; Sirolli, V.; Arduini, A.; Liberato, L.D.; Pietro, N.D. Erythrocyte Alterations and Increased Cardiovascular Risk in Chronic Renal Failure. Nephro-Urol. Mon. 2017, 9, e45866. Available online: https://sites.kowsarpub.com/num/articles/55539.html (accessed on 29 July 2020). [CrossRef]

3. Chaleckis, R.; Murakami, I.; Takada, J.; Kondoh, H.; Yanagida, M. Individual variability in human blood metabolites identifies age-related differences. Proc. Natl. Acad. Sci. USA 2016, 113, 4252–4259. [CrossRef] [PubMed]

4. Rübsaamen, K. Lipidomic Analysis of Circulating Human Blood Cells. Ph.D. Thesis, Der Naturwissenschaftlichen Fakultät III—Biologie und Vorklinische Medizin der Universität Regensburg, Regensburg, Germany, 2010.

5. Harada, T.; Yuba-Kubo, A.; Sugiu, Y.; Zaima, N.; Hayasaka, T.; Goto-Inoue, N.; Wakui, M.; Suematsu, M.; Takeshita, K.; Ogawa, K.; et al. Visualization of Volatile Substances in Different Organelles with an Atmospheric-Pressure Mass Microscope. Anal. Chem. 2009, 81, 9153–9157. [CrossRef] [PubMed]

6. Van de Plas, R.; Yang, J.; Spraggins, J.; Caprioli, R.M. Image fusion of mass spectrometry and microscopy: A multimodality paradigm for molecular tissue mapping. Nat. Methods 2015, 12, 366–372. [CrossRef] [PubMed]

7. Porta Siegel, T.; Hamm, G.; Bunch, J.; Cappell, J.; Fletcher, J.S.; Schwamborn, K. Mass Spectrometry Imaging and Integration with Other Imaging Modalities for Greater Molecular Understanding of Biological Tissues. Mol. Imaging Biol. 2018, 20, 888–901. [CrossRef] [PubMed]

8. Buchberger, A.R.; DeLaney, K.; Johnson, J.; Li, L. Mass Spectrometry Imaging: A Review of Emerging Advancements and Future Insights. Anal. Chem. 2018, 90, 240–265. [CrossRef]

9. Sugiyama, E.; Yao, I.; Setou, M. Visualization of local phosphatidylcholine synthesis within hippocampal neurons using a compartmentalized culture system and imaging mass spectrometry. Biochem. Biophys. Res. Commun. 2018, 495, 1048–1054. [CrossRef]

10. Spivey, E.C.; McMillen, J.C.; Ryan, D.J.; Spraggins, J.M.; Caprioli, R.M. Combining MALDI-2 and transmission geometry laser optics to achieve high sensitivity for ultra-high spatial resolution surface analysis. J. Mass Spectrom. 2019, 54, 366–370. [CrossRef]

11. Zavalin, A.; Todd, E.M.; Rawhouser, P.D.; Yang, J.; Norris, J.L.; Caprioli, R.M. Direct imaging of single cells and tissue at sub-cellular spatial resolution using transmission geometry MALDI MS. J. Mass Spectrom. 2012, 47, 1473–1481. [CrossRef]

12. Gorman, B.L.; Kraft, M.L. High-Resolution Secondary Ion Mass Spectrometry Analysis of Cell Membranes. Anal. Chem. 2020, 92, 1645–1652. [CrossRef]

13. Spengler, B.; Huber, M.; Kaufmann, R. MALDI Ion Imaging and Biological Ion Imaging with a new Scanning UV-Laser Microprobe. In Book of Abstracts of 42nd Annual Conference on Mass Spectrometry and Allied Topics; American Society for Mass Spectrometry: Chicago, IL, USA, 1994; p. 1041. [CrossRef]

14. Sandra, K.; Pereira, A.D.S.; Vanhoenacker, G.; David, F.; Sandra, P. Comprehensive blood plasma lipidomics by liquid chromatography/quadrupole time-of-flight mass spectrometry. J. Chromatogr. A 2010, 1217, 4087–4099. [CrossRef] [PubMed]

15. Annesley, T.M. Ion suppression in mass spectrometry. Clin. Chem. 2003, 49, 1041–1044. [CrossRef] [PubMed]

16. Hankin, J.A.; Barkley, R.M.; Murphy, R.C. Sublimation as a method of matrix application for mass spectrometric imaging. J. Am. Soc. Mass Spectrom. 2007, 18, 1646–1652. [CrossRef] [PubMed]
17. Soltwisch, J.; Kettling, H.; Vens-Cappell, S.; Wiegelmann, M.; Müthing, J.; Dreisewerd, K. Mass spectrometry imaging with laser-induced postionization. *Science* **2015**, *348*, 211–215. [CrossRef] [PubMed]

18. Wiegelmann, M.; Dreisewerd, K.; Soltwisch, J. Influence of the Laser Spot Size, Focal Beam Profile, and Tissue Type on the Lipid Signals Obtained by MALDI-MS Imaging in Oversampling Mode. *J. Am. Soc. Mass Spectrom.* **2016**, *27*, 1952–1964. [CrossRef]

19. Leopold, J.; Popkova, Y.; Engel, K.M.; Schiller, J. Recent Developments of Useful MALDI Matrices for the Mass Spectrometric Characterization of Lipids. *Biomolecules* **2018**, *8*, 173. [CrossRef]

20. Nakashima, K.; Nakashima, H.; Shimoyama, M. Deoxyadenosine triphosphate acting as an energy-transferring molecule in adenine deaminase inhibited human erythrocytes. *Biochim. Biophys. Acta* **1991**, *1094*, 257–262. [CrossRef]

21. Gieseg, S.P.; Baxter-Parker, G.; Lindsay, A. Neopterin, Inflammation and Oxidative Stress: What Could We Be Missing? *Antioxidants* **2018**, *7*, 80. [CrossRef]

22. Inai, T.; Mihara, H.; Kurihara, T.; Esaki, N. Selenocysteine is selectively taken up by red blood cells. *Biosci. Biotechnol. Biochem.* **2009**, *73*, 2746. [CrossRef]

23. Duclos, R.I.; Cleary, D.C.; Catcott, K.C.; Zhou, Z.S. Synthesis and characterization of Se-adenosyl-L-selenohomocysteine selenoxide. *J. Sulfur Chem.* **2015**, *36*, 135–144. [CrossRef]

24. Mendel, R.R. The Molybdenum Cofactor. *J. Biol. Chem.* **2013**, *288*, 13165–13172. [CrossRef] [PubMed]

25. Wishart, D.S.; Feunang, Y.D.; Marcu, A.; Guo, A.C.; Liang, K.; Vázquez-Fresno, R.; Sajed, T.; Johnson, D.; Li, C.; Karu, N.; et al. HMDB 4.0: The human metabolome database for 2018. *Nucleic Acids Res.* **2018**, *46*, D608–D617. [CrossRef] [PubMed]

26. Kanehisa, M.; Goto, S. KEGG: Kyoto Encyclopedia of Genes and Genomes. *Nucleic Acids Res.* **2000**, *28*, 27–30. [CrossRef] [PubMed]